Category: Cardiac Assist DevicesSyndicate content

HeartWare closes $8M World Heart buyout

August 3, 2012 by MassDevice staff

HeartWare International closed its $8 million buyout of erstwhile rival Word Heart Corp.

HeartWare International
World Heart Corp.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

R&D expenses clip Thoratec's profits, shares slide more than 6%

August 3, 2012 by MassDevice staff

Shares of Thoratec Corp. lost more than 6% today after the medical device company said its 2nd-quarter profits were down nearly 5% on increased operating costs, largely from higher spending on research & development.

Thoratec

Thoratec (NSDQ:THOR) shares lost more than 6% yesterday after the heart pump maker said its operating costs spiked 20%, largely due to ramped-up R&D efforts, and drove a nearly 5% profit slide.

MassDevice.com +3 | The top 3 med-tech stories for May 9, 2012.

May 9, 2012 by MassDevice staff

The DePuy hip battle wages on in the pages of the British Medical Journal, St. Jude lands FDA wins for CRM devices reducing unneeded shocks and HeartWare closes enrollment in destination therapy trial for heart pump.

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else today, make sure you're still in the know with MassDevice +3.

HeartWare closes enrollment in destination therapy trial for heart pump | Wall Street Beat

May 9, 2012 by MassDevice staff

HeartWare announced that it completed enrollment in a 450-patient clinical trial considering its HVAD pump as a destination therapy for patients with advanced heart failure; also, 2011 was a good year for angel investment; Bayer considers ditching diabetes business; iCad gets a stay of execution from Nasdaq delisting; INC Research expands a electronic data management partnership with Medidata; and Kimberly Clark renews a sterilization wrap contract with HealthTrust; plus, a Funding Roundup and analysts' ups and downs.

MassDevice.com Wall Street Beat

HeartWare International (NSDQ:HTWR) completed enrollment in a 450-patient pivotal trial considering its ventricular assist system as a destination therapy for patients with advanced heart failure.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Thoratec kills it in Q1, Wall Street shrugs | Earnings Roundup

May 2, 2012 by MassDevice staff

Thoratec leaves Wall Street analysts in the dust with its 1st quarter earnings, beating expectations by 10¢, but the initial bump fades as investors back off after sending shares up more than 7% this morning; also, Allergan's Q1 sales rise, earnings soar; Endologix's sales spike, losses soar; Q1 profits plunge for Greatbatch; Hospira's Q1 sales slip, earnings slide; ResMed's Q3 sales, earnings up; and more.

MassDevice.com news

Thoratec (NSDQ:THOR) started today up 7.2% as investors reacted to its stellar 1st-quarter numbers, but by the time the market closed THOR shares had fallen back to Earth to close at $34.46, down 0.1%.

The heart pump maker posted profits of $25.5 million, or 43¢ per diluted share, on sales of $126.8 million for the 3 months ended March 31.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Thoratec kills it in Q1, Wall Street shrugs

May 2, 2012 by MassDevice staff

Thoratec leaves Wall Street analysts in the dust with its 1st quarter earnings, beating expectations by 10¢, but the initial bump fades as investors back off after sending shares up more than 7% this morning.

MassDevice.com news

Thoratec (NSDQ:THOR) started today up 7.2% as investors reacted to its stellar 1st-quarter numbers, but by the time the market closed THOR shares had fallen back to Earth to close at $34.46, down 0.1%.

The heart pump maker posted profits of $25.5 million, or 43¢ per diluted share, on sales of $126.8 million for the 3 months ended March 31.

HeartWare wins FDA panel nod

April 25, 2012 by MassDevice staff

MassDevice.com news

An FDA advisory panel recommended approval for HeartWare International's (NSDQ:HTWR) HVAD implantable heart pump for people with end-stage heart failure.

The watchdog agency's circulatory devices panel said the agency should approve the left ventricular assist device for use as a so-called "bridge to transplant" for patients waiting for a heart transplant.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp